Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Pharma-Bio Serv (PBSV) over the last 16 years, with Q4 2025 value amounting to $1.4 million.

  • Pharma-Bio Serv's Cost of Revenue fell 1282.35% to $1.4 million in Q4 2025 from the same period last year, while for Oct 2025 it was $6.1 million, marking a year-over-year decrease of 1290.07%. This contributed to the annual value of $6.1 million for FY2025, which is 1290.07% down from last year.
  • As of Q4 2025, Pharma-Bio Serv's Cost of Revenue stood at $1.4 million, which was down 1282.35% from $1.4 million recorded in Q3 2025.
  • In the past 5 years, Pharma-Bio Serv's Cost of Revenue ranged from a high of $4.1 million in Q4 2021 and a low of $1.4 million during Q3 2025
  • Its 5-year average for Cost of Revenue is $2.7 million, with a median of $3.0 million in 2023.
  • As far as peak fluctuations go, Pharma-Bio Serv's Cost of Revenue surged by 1895.0% in 2022, and later tumbled by 4531.22% in 2024.
  • Over the past 5 years, Pharma-Bio Serv's Cost of Revenue (Quarter) stood at $4.1 million in 2021, then decreased by 13.88% to $3.5 million in 2022, then fell by 24.4% to $2.7 million in 2023, then crashed by 39.79% to $1.6 million in 2024, then dropped by 12.82% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q4 2025, $1.4 million for Q3 2025, and $1.6 million during Q2 2025.